Fish oil has long been praised as brain-boosting, but new research suggests the story may be more complicated. Scientists found that in people with repeated mild head injuries, a key omega-3 fatty acid in fish oil—EPA—may actually interfere with the brain’s ability to repair itself. Instead of helping recovery, it appears to weaken blood vessel stability, disrupt healing signals, and even contribu
Nancy Cox, a CDC veteran who for decades was a global leader in influenza research, has died at 77.
A gut bacterium may be quietly fueling depression through an unexpected chemical twist. Researchers found that when Morganella morganii interacts with a common pollutant, it produces a molecule that triggers inflammation—something strongly linked to depression. This finding helps explain how gut microbes can influence brain health at a molecular level. It also raises the possibility of new treatme
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
Trump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.
What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts has some answers.
A Utah pilot to renew prescriptions using a bot faced backlash from the state's medical board, which called for an immediate suspension.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
After recalibrating its production strategy in the late 2010s to help meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential approval of a next-generation multiple myeloma cell therapy later this year.
In today's Morning Rounds newsletter, a new era in GOP drug policy, an international childhood vaccine campaign grows, and more.
President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer reception in Europe.
After a series of setbacks for Sanofi’s tolebrutinib, the French company has scored a victory for the multiple sclerosis candidate.
The FDA rejected two new products from AbbVie and Grace Therapeutics, citing manufacturing-related concerns.
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its new indication and power the franchise to peak sales of $3.1 billion, Guggenheim Securities analysts predicted in a note to investors.
Daiichi Sankyo has postponed its annual report by two weeks, citing additional time needed to review “the supply plans for its oncology products portfolio and development pipeline.”
Roche’s Genentech unit is launching a new multimedia campaign aimed at sharing the stories of people living with diabetes and the impact the disease can have on their vision.
During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has affected its Ireland operations in several ways. Now, more employees in the country are set to lose their jobs by the end of the year.
Starting residency at 72 isn’t for the faint of heart. But that’s what Dawn Zuidegeest-Craft is doing.
In this week’s STATus Report, host Alex Hogan chats with STAT Washington correspondent Daniel Payne about Trump's psychedelics EO.